Calysta Energy Stock
Calysta Energy develops a new biological gas-to-liquids™ (BioGTL™) and biological gas-to-chemicals (BioGTC™) technology using natural gas.
Sign up today and learn more about Calysta Energy Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Calysta Energy Stock
Calysta Energy (www.calystaenergy.com), Menlo Park, CA., is developing a new biological gas-to-liquids™ (BioGTL™) and biological gas-to-chemicals (BioGTC™) technology using methane – an energy-rich component of natural gas – as a new sustainable biological feedstock for high value industrial chemicals and transportation fuels with cost and performance advantages over current processes. The company is a spinout of DNA2.0, the largest US-based provider of synthetic genes for industrial and academic use.
Funding History
| May 2011 | $5.0M |
|---|---|
| December 2013 | $3.0M |
| January 2015 | $10.0M |
| February 2016 | $30.0M |
| May 2017 | $40.0M |
Management
Chief Financial Officer and Chief Sustainability Officer
Lynsey Wenger
Vice President, Biological Engineering
Lori Giver
Co-founder
David McElroy
President and Chief Executive Officer
Alan Shaw
Vice President, Global Capital Projects
Graham Aylen
Chief Product and Innovation Officer
Josh Silverman
Vice President, Business Development
Dennis Leong
Vice President, Nutrition
Arild Johannessen
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
